HLA-B*5701 frequency in Chilean HIV-infected patients and in general population

Brazilian Journal of Infectious Diseases

Solari, Sandra¹  Poggi, Helena¹  Rodríguez P, Luis¹  Vera, Alejandra¹  Lagos, Marcela¹  Pérez, Carlos M¹ 

[1] Pontificia Universidad Católica de Chile, Santiago, Chile

关键词: HLA-B*5701;    HIV;    abacavir;    Chile;    pharmacogenetics;   

DOI  :  10.1590/S1413-86702010000500015

来源: Contexto

【 摘 要 】

It has been demonstrated that HLA-B*5701 screening reduces the risk for hypersensitivity reaction to abacavir in HIV-infected patients. Since B*5701 prevalence varies among different populations, it is important to determine the carrier frequency prior to its use for the screening of HIV-infected patients.The aim of this study was to determine HLA-B*5701 carrier frequency in Chilean general population and HIV-infected patients referred for B*5701 typing. For that purpose 300 blood bank donors and 492 abacavir-naïve HIV-infected patients from Chile were screened for B*5701 by a sequence specific primer PCR.We detected 14/300 (4.7%) B*57-positive individuals in the Chilean general population, 11 (3.7%) were B*5701 positive, and 3 (1%) had another subtype.All were heterozygous,thus a B*5701 allele frequency of 2% was determined.Eleven of 492 (2.2 %) HIV-patients carried a B*5701 allele. The difference between these frequencies is probably due to slow progression of HIV infection in HLA-B*5701 carriers, thus less patients would require antiretroviral therapy and B*5701 typing. Considering the usefulness of B*5701 screening, its prevalence in the Chilean general population,and the availability of a validated method,we conclude that HLA-B*5701 typing in Chilean HIV-infected patients about to initiate abacavir treatment is strongly recommended.

【 授权许可】

CC BY-NC-ND